Strides Pharma Science and its subsidiary, Universal Corporation (UCL) (Kenya) have entered into a voluntary non?exclusive sub?license partnership with Medicines Patent Pool (MPP) to commercialize molnupiravir in the international markets.
MPP’s partnership to enable a global reach for molnupiravir. Strides and UCL will manufacture the product at their WHO PQ facilities in India and Nairobi, Kenya. UCL owns and operates one of the two WHO PQ facilities in the Sub?Saharan region.
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS?CoV?2, and clinical studies have shown this drug to be active against the most common Covid?19 variants.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
